Using BRCA1- and BRCA2-deficient cell lines and mouse xenografts, Bryant et al. [15] and Farmer et al. [16] demonstrated marked in vitro and in vivo cytotoxicity of PARPi monotherapy in tumor cells with intrinsic HR deficiency, with close to no effect on BRCA-proficient cells. Here, BRCA1 is linked to neoplasm.